Natera, Inc. (NTRA) CEO Steve Chapman on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
New Publication in Nature Cancer Demonstrates Signatera's Ability to Evaluate Tumor Response to ImmunotherapyPRNewsWire • 08/03/20
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD TestingPRNewsWire • 06/18/20
Natera Launches Quantification Technique to Enhance Prospera™ Test Precision; Initiates PEDAL Study for New InsightsPRNewsWire • 06/01/20
Natera Announces New Prospera™ Data at ATC Showcasing Innovation in Cell-Free DNAPRNewsWire • 05/26/20
Natera Announces New Data at ASCO Highlighting Utility of Personalized MRD MonitoringPRNewsWire • 05/19/20
Natera, Inc. (NTRA) CEO Steve Chapman on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/09/20
Natera Scores Relative Strength Rating Upgrade; Hits Key BenchmarkInvestors Business Daily • 03/23/20
Natera Inc. (NTRA) CEO Steve Chapman on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/27/20
Natera's (NTRA) CEO Steve Chapman on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19